ArticleFrontiers in oncology2022
Role of cuproptosis-related gene in lung adenocarcinoma.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Process Optimization of Novel Boronophenylalanine Liposomes Through Box-Behnken Response Surface Design and Preliminary Evaluation in A549 Lung Carcinoma Cells for Boron Neutron Capture Therapy.Molecules (Basel, Switzerland) · 2026Article
- Machine learning-based model identifies a novel cuproptosis-related mitochondrial gene signature with a key role in the prognosis and treatment of lung adenocarcinoma.Oncology letters · 2025Article
- Dysregulation of SIGLEC1 in non-small cell lung cancer: prognostic implications and immunomodulatory role-a multicenter cohort study.Journal of cancer research and clinical oncology · 2024Article
- Role of cuproptosis in mediating the severity of experimental malaria-associated acute lung injury/acute respiratory distress syndrome.Parasites & vectors · 2024Article
- Cuproptosis in lung cancer: therapeutic options and prognostic models.Apoptosis : an international journal on programmed cell death · 2024Review
- Recent advances in copper homeostasis-involved tumor theranostics.Asian journal of pharmaceutical sciences · 2024Review
- MTF1 genetic variants are associated with lung cancer risk in the Chinese Han population.BMC cancer · 2024Article
- Analysis of cuproptosis-related genes in prognosis and immune infiltration in grade 4 diffuse gliomas.Heliyon · 2024Article
- Analysis of the potential biological value of pyruvate dehydrogenase E1 subunit β in human cancer.World journal of gastrointestinal oncology · 2024Article
- Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma.BMC medical genomics · 2024Article
- GLIPR2: a potential biomarker and therapeutic target unveiled - Insights from extensive pan-cancer analyses, with a spotlight on lung adenocarcinoma.Frontiers in immunology · 2024Article
- Identification of a Novel Cuproptosis-Related Gene Signature and Integrative Analyses in Thyroid Cancer.Journal of clinical medicine · 2023Article
- Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, which is the leading cause of cancer death. Dysregulation of cell proliferation and death plays a crucial role in the development of LUAD. As of recently, the role of a new form of cell death, cuproptosis, and it has attracted more and more attention. As of yet, it is not clear whether cuproptosis is involved in the progression of LUAD. Methods: An integrated set of bioinformatics tools was utilized to analyze the expression and prognostic significance of cuproptosis-related genes. Meanwhile, a robust risk signature was developed using machine learning based on prognostic cuproptosis-related genes and explored the value of prognostic cuproptosis-related signature for clinical applications, functional enrichment and immune landscape. Lastly, the dysregulation of the cuproptosis-related genes in LUAD was validated by Results: In this study, first, cuproptosis-related genes were found to be differentially expressed in LUAD patients of public databases, and nine of them had prognostic value. Next, a cuproptosis-related model with five features (DLTA, MTF1, GLS, PDHB and PDHA1) was constructed to separate the patients into high- and low-risk groups based on median risk score. Internal validation set and external validation set were used for model validation and evaluation. What's more, Enrichment analysis of differential genes and the WGCNA identified that cuproptosis-related signatures affected tumor prognosis by influencing tumor immunity. Small molecule compounds were predicted based on differential expressed genes to improve poor prognosis in the high-risk group and a nomogram was constructed to further advance clinical applications. In closing, our data showed that FDX1 affected the prognosis of lung cancer by altering the expression of cuproptosis-related signature. Conclusion: A new cuproptosis-related signature for survival prediction was constructed and validated by machine learning algorithm and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.